Chunkit Fung, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-9484

Office: (585) 275-5823

Fax: (585) 273-1042

A member of the University of Rochester Medical Faculty Group

An Accountable Health Partner

Accepting New Patients

Locations

James P. Wilmot Cancer Center
601 Elmwood Ave
Rochester, NY 14642

Faculty Appointments

Professor - Department of Medicine , Hematology/Oncology (SMD)
Associate Chair, Diversity, Equity and Inclusion - Department of Medicine (SMD)
Professor - Cancer Center - Joint
Professor - Department of Public Health Sciences (SMD) - Joint

Patient Care Settings

Cancer, Hospital Medicine

Biography

I chose this specialty because of the many exciting new therapeutic options for patients with genitourinary cancers, as well as the opportunity to become an integral part of a team that cares for patients during one of their most difficult times.

As my patient, you can depend on me for compassion and dedication, in addition to an innovative and patient-centered approach to care. My research interests are clinical trials for genitourinary cancers and cancer survivorship research. During my free time, I enjoy running, hiking, cooking and travel.

Conditions I Treat

- Prostate cancer
- Bladder cancer
- Testicular cancer
- Kidney cancer
- Adrenal cancer

Professional Background

Dr. Chunkit Fung graduated Summa Cum Laude with Distinction in Research from Cornell University in 2000. He then went on to Medical School at the University of Pennsylvania in Philadelphia, PA and graduated with his M.D in 2004. He completed his internal medicine Internship and Residency from 2004 through 2007 at the Hospital of the University of Pennsylvania. He held the position of Instructor in the Department of Medicine from the University of Pennsylvania from 2007 to 2008 and subsequently completed his Fellowship in Hematology and Oncology at the Hospital of the University of Pennsylvania from 2008 to 2011. He also received a Master in Clinical Epidemiology in 2012 from the University of Pennsylvania School in Medicine. In July 2011, he came to the University of Rochester School of Medicine and Dentistry as an Assistant Professor in the Department of Hematology and Oncology. His clinical research interests are developing clinical trials to evaluate new therapies in Genitourinary Oncology and Cancer Survivorship Research.

Research

I am a medical oncologist specialized in genitourinary malignancy and an Assistant Professor of medicine with research interests in cancer control, particularly in the development, implementation, and dissemination of mHealth behavioral interventions to prevent and manage treatment- and cancer-related toxicities in cancer survivors, with a specific focus in cardiovascular complications from cancer treatment. Additionally, I am interested in developing clinical trials to evaluate new therapeutics for treatment of urologic malignancies.

Credentials

Specialties

Education

2004
MD | University of Pennsylvania School of Medicine

Post-doctoral Training & Residency

07/01/2008 - 06/01/2011
Fellowship in Hematology & Oncology at Hospital of the University of Pennsylvania GME

07/01/2006 - 06/30/2007
Residency in Internal Medicine at Hospital of the University of Pennsylvania GME

06/01/2004 - 06/30/2006
Internship in Internal Medicine at Hospital of the University of Pennsylvania GME

VIEW ALL

Awards

2020
Human Rights Campaign Leadership Award for Rising Star Gala Leaders

2019
Presidential Diversity Award Nominee, University of Rochester

2018 - 2018
Civic Leadership Award
Sponsor: US TOO Prostate Cancer Support Group
Location: Rochester, NY

2018
URMC Wilmot Cancer Institute, Hematology/Oncology Fellowship Training Program, Teacher of the Year 2017/2018

2016 - 2018
Empire Clinical Research Investigator Program Fellowship Grant

2016
Strong Star Certificate of Appreciation

2015
Strong Star Certificate of Appreciation

2014
Strong Star Certificate of Appreciation

2013
Strong Star Certificate of Appreciation

2012 - 2015
Wimot Cancer Center Research Fellowship
Sponsor: Wimot Cancer Center

2012
National Institute of Health Loan Repayment Program Grant
Sponsor: National Institute of Health (NIH)

2012
Patient and Family Centered Care Award

2012
Strong Star Certificate of Appreciation

2011
American Society of Clinical Oncology Trainee Travel Award
Sponsor: American Society of Clinical Oncology

2010
National Institute of Health Loan Repayment Program
Sponsor: National Institute of Health

2010
NCCN Fellow Recognition Program

2001
American Heart Association Cardiovascular Disease and Stroke Fellowship
Sponsor: American Heart Association

2000
Summa Cum Laude with Distinction in Research
Sponsor: Cornell University

2000
Golden Key National Honor Society

1999
Howard Hughes Medical Institute Undergraduate Research Scholarship
Sponsor: Howard Hughes Medical Institute

1996
Valedictorian
Location: Brooklyn Technical High School

VIEW ALL

Clinical Trials

A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

Lead Researcher: Chunkit Fung

This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.

View Study Details

UGUK17036: Monitoring of Treatment Related Toxicities from Oral Targeted Agents and Immunotherapy Among Patients with Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study.

Lead Researcher: Chunkit Fung

To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-related toxicities, quality of life, distress level, and drug adherence.

View Study Details

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Lead Researcher: Chunkit Fung

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

View Study Details

DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Lead Researcher: Chunkit Fung

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.

View Study Details

Publications

Journal Articles

11/15/2023
Dinh PC, Monahan PO, Fosså SD, Sesso HD, Feldman DR, Dolan ME, Nevel K, Kincaid J, Vaughn DJ, Martin NE, Sanchez VA, Einhorn LH, Frisina R, Fung C, Kroenke K, Travis LB. "Impact of Pain and Adverse Health Outcomes on Long-term U.S. Testicular Cancer Survivors." Journal of the National Cancer Institute.. 2023 Nov 15; Epub 2023 Nov 15.

10/11/2023
Travis LB, Feldman DR, Fung C, Poynter JN, Lockley M, Frazier AL. "Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2023 Oct 11; :JCO2301099. Epub 2023 Oct 11.

10/4/2023
Kamen CS, Dizon DS, Fung C, Pratt-Chapman ML, Agulnik M, Fashoyin-Aje LA, Jeames SE, Merrill JK, Smith KT, Maingi S. "State of Cancer Care in America: Achieving Cancer Health Equity Among Sexual and Gender Minority Communities." JCO oncology practice.. 2023 Oct 4; :OP2300435. Epub 2023 Oct 04.

Books & Chapters

2017
Chapter Title: Second Cancers
Book Title: Cancer: Principles & Practice of Oncology, 11th Edition
Author List: Fung, C., Bhatia, S., Allan, J.M., Oeffinger, K.C., Ng, A., Travis L.B.
Edited By: DeVita, V.T. Jr., Lawrence, TS., Rosenberg, S.A.
Published By: Wolters Kluwer Health 2017 in Philadelphia

2014
Chapter Title: Neurotoxicity and Ototoxicity Among Testicular Cancer Survivors
Book Title: EAU-ICUD Consultation on Medical Treatment of Urological Malignancies
Author List: Fung, C., Qi, J, Oldenburg, J
Edited By: Massard C, Zhou FJ, Fossa SD
Published By: EAU-ICUD 2014

2014
Chapter Title: Second Malignant Neoplasms and Cardiovascular Disease Among Testicular Cancer Survivors
Book Title: Testicular Cancer: Diagnosis and Clinical Management
Author List: Fung, C., Fossa SD, Travis LB
Edited By: Einhorn LH, Horwich A, Huddart R
Published By: Oxford: Blackwell Publishing 2014

VIEW ALL PUBLICATIONS